PR Newswire Clinical TrialsOriginal article
Caliway Announces Positive Phase 2 Results of CBL-514 in Dercum's Disease, Achieving Primary Endpoint with Statistically Significant and Sustained Pain Reduction
Phase 2positiveCBL-514Positive
AI Analysis
Summary
Caliway announced positive Phase 2 results for CBL-514 in Dercum's Disease, achieving its primary endpoint with statistically significant and sustained pain reduction compared to placebo. The company indicates potential for expansion of CBL-514 development beyond Dercum's Disease.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Outcome Details
Statistically significant and sustained pain reduction achieved compared with placebo across FAS and PP populations
Importance:7/10
Sentiment:
0.85
Phase 2 datapain reductionprimary endpoint metDercum's Diseasepositive trial results
Read the original article
Published by PR Newswire Clinical Trials on September 23, 2026 2:08 AM